Document:

STEM CELL THERAPY INTERNATIONAL, INC.

               SCTI MEDICAL AND SCIENTIFIC ADVISORY BOARD AGREEMENT

     THIS  AGREEMENT is made this 2nd day of December, 2005, by and between STEM
CELL THERAPY INTERNATIONAL, INC.; a corporation duly incorporated under the laws
of Nevada, with its principal office located at 2203 North Lois Ave., 9th Floor,
Tampa,  Florida 33594 ("the Company''), and DR. NIKITA TREGUBOV, MD. as a member
of  the  SCTI  Medical  and  Scientific  Advisory Board, herein ("the Advisor").

     In  consideration  of the mutual agreements contained in this document, the
parties,  intending  to  be  legally  bound,  agree  as  follows:

 1.     INDEPENDENT  CONTRACTOR.

     The  Advisor  will  be an independent contractor and not an Employee of the
Company  and  will  determine  will  determine  the  method  of operation in the
performance  of  allo  (human)  stem  cell  biological  solution  and  tissue
transplantations  and/or  any  other  stem  cell  transplantation  therapy.

     The  Advisor  will not be entitled to receive any compensation, commissions
or  benefits  other  than  those  expressly  provided  in  this  Agreement.

 2.     SCOPE  OF  DUTIES.

(a)     The  Advisor  certifies  that  there  are  no  outstanding agreements or
obligations  that conflict with any of the provisions of this Agreement, or that
would  preclude  or  in  any  way  compromise the Advisor in compliance with the
provisions  hereof.

(b)     The  Advisor agrees to actively participate in the Company's Medical and
Scientific  Advisory  Board and to review patient's medical chart and records as
provided  by  the  Company and to provide the Company a written report detailing
recommendations  for  the  appropriate  course  of  stem cell therapy treatment.

(c)     The  Advisor agrees to participate in conference calls and meetings with
the  SCTI  Corporate  Officers  and  other  members of the Company's Medical and
Scientific  Advisory  Board  when his/her schedule allows, to discuss the latest
technology  in  stem  cell  treatments  and  shall  contribute  with  his/her
recommendations  on  future  progress  and  corporate  direction.

(d)     The  Advisor will be required to interact with both treating Physicians,
current  and  potential  patients  to  determine  the  scope  of  treatments,
documentation  policies,  proof of efficacy issues, as well as develop strategic
alliances  with  other  organizations and individuals outside of the Company for
the advancement of our knowledge and expertise in the treatment of patients with
our  various  stem  cell  Products.

(e)     The  Advisor's roll will be to make sure that the Company shall maintain
its competitive edge both globally and in the United States in the field of stem
cell  treatments  and  research.

(f)     The  Advisor  will  also  be responsible for consulting with the medical
clinic  in  Kiev,  assist in proof reading and writing abstracts and articles on
our  patients,  help establish clinics in the UK, Germany, Switzerland and Dubai
in  2006.

(g)     The  Advisor  will be available via cell phone to consult with potential
patients,  other  Board  Advisors  and  treating  physicians.

3.     COMPENSATION.

     The  Company  shall  issue  ten thousand (10,000) shares of Rule 144 common
stock  of  the  Company  to the Advisor as compensation for the initial one year
term  of  this  agreement,  as  follows:

     (a)     Thirty  days  after  the  execution  of this agreement, the Company
shall  issue  five  thousand  (5,000) shares of common stock under rule 144, and

     (b)     Six months after the execution of this agreement, the Company shall
issue  the  remaining  five thousand (5,000) shares common stock under rule 144.

     (c)     Compensation  for  successive renewal years under the terms of this
Agreement  shall  be  issued  at thirty days and six months after renewal in two
increments  of  five  thousand  shares  of  rule  144  common  stock.

4.     TERM.

This  Agreement will become effective on the date of execution and will continue
in  full  force  and  effect for a minimum period of one (1) year and thereafter
from year to year unless and until terminated by a party in accordance with this
Agreement.

5.     TERMINATION.

During  the  minimum  period  of  one  (1)  year,  either  party may immediately
terminate  this  Agreement  for  cause,  upon  written  notice for any breach of
contract,  if  the other party does not cure a material breach of this Agreement
within  thirty  (30)  days  of  receipt of written notice detailing such breach.
After  the  expiration  of  one  (1)  year  from  the  date of execution of this
agreement,  either  party  may  terminate  this  Agreement without cause and for
convenience with fourteen (14) days prior written notice to the other party.  At
any time, the parties may mutually agree in writing to terminate this Agreement.

6.     CONFIDENTIALITY.

          The  Advisor  shall  not  use  or divulge or communicate to any person
(other  than  those  whose  province  it  is to know the same or as permitted or
contemplated  by  this Agreement or with the written approval of the other party
or  as  may  be  required  by  law):
(i)                 any  Confidential  Company  Information;  or
(ii)                any  of  the  terms  of  this  Agreement

     The Advisor shall prevent the unauthorized publication or disclosure of any
such  information, materials or documents and ensure that any person to whom the
information,  materials  or  documents  are  disclosed is aware that the same is
confidential  and  is  covered  by  a  similar duty to maintain confidentiality.
     The  Advisor  shall  ensure  that  any  employees,  consultants,  agents or
advisors  are  aware  of  and comply with the confidentiality and non-disclosure
provisions contained in this Section and shall indemnify the Company against any
loss  or damage which the Company may sustain or incur as a result of any breach
of  the  terms  hereof  by the Advisor, or any employees, consultants, agents or
advisors.

     CONFIDENTIAL  INFORMATION.

     The Advisor shall not directly or indirectly, communicate, disclose or
divulge to any person or entity, or use for their own benefit or the benefit of
any person or entity, any knowledge or information which the Advisor may have
acquired, no matter from whom or on what matter such knowledge or information
may have been acquired from the Company.
<PAGE>
These  provisions shall survive the expiration or termination of this Agreement.

7.     COVENANT  NOT  TO  COMPETE.

     The  Advisor,  during  the Term hereof, and for an additional period of two
years  thereafter  (the  ``Non-competition  Term''),  may  not:

(a)     Engage  or  participate  in or become employed by, or render advisory or
other  services  to,  any  business entity that competes with the Company in the
Ukraine  or  the  Dominican  Republic.

     If  the  foregoing  provision  is determined to be invalid by reason of the
length  of  any  period  or the size of the area set forth, such period of time,
such  area  or both will be considered to be reduced to a period of time or area
that  will  cure  such  invalidity.

(b)     Directly  or  indirectly  solicit  or induce any person, corporation, or
other  entity  that is a customer of the Company at the time of the execution of
this  agreement  or  that  was a customer at any time within the one-year period
immediately preceding such termination to become a customer of any other person,
corporation,  or  other  entity  competing  with  the Company or its Parent. The
Advisor  further  agrees  that  he  or  she  will  not approach any such person,
corporation,  or  other  entity  for  such  purposes.

(c)     Directly  or  indirectly solicit or induce any person who is an Employee
of  the  Company  or  its  Parent  to  become  employed  by  any person, firm or
corporation  competing  with the Company or its Parent, or approach any Employee
for  such  purpose.

(d)     Disclose  any  proprietary or confidential information of the Company or
its Parent relating to (i) the customers, clients, employees and accounts of the
Company  or  its  Parent,  including  but  not  limited  to  the identity of the
Company's  or  its  Parent's  customers  if  such  identity  is  proprietary  or
confidential;  (ii)  the  Company's  or  its Parent's business methods, systems,
plans,  policies,  and personnel; or (iii) the technical data, trade secrets, or
know-how  of the Company or its Parent, including, but not limited to, research,
product  plans, products, services, markets, software, developments, inventions,
processes,  formulas,  technology,  designs,  drawings,  engineering,  hardware,
configuration  information,  marketing,  finances  or other business information
disclosed  by  the Company or its Parent, either directly or indirectly, whether
in  writing,  orally  or  by  drawings  or  inspection  of  parts  or equipment.

8.     ARBITRATION  OF  DISPUTES.

(a)     The  Company  and  the  Advisor  agree  that  any dispute or controversy
arising  out  of or relating to any interpretation, construction, performance or
breach  of  this  Agreement,  will  be  settled  by  arbitration  to  be held in
Philadelphia  County,  Pennsylvania, in accordance with the rules then in effect
of the American Arbitration Association. The arbitrator may grant injunctions or
other  relief  in  the  dispute  or  controversy.

(b)     The  decision of the arbitrator will be final, conclusive and binding on
the  parties  to  the  arbitration.  Judgment may be entered on the arbitrator's
decision  in  any  court  of competent jurisdiction. The Company and The Advisor
will each pay one-half of the cost and expenses of the arbitration and each will
separately  pay  its  respective  counsel  fees  and  expenses.

     The  Advisor  acknowledges  that the services to be rendered by the Advisor
are  of  a  special, unique and extraordinary character, and in  connection with
such services, the Advisor will have access to confidential information vital to
the  Company's  and its Parent's business. By reason of this, the Advisor agrees
that  if  the  Advisor  violates  any  of  the provisions of this Agreement with
respect  to non-competition, diversion of the Company's and its Parent's clients
or  employees,  or  confidentiality,  the  Company  and the Parent would sustain
irreparable  harm,  and  therefore,  in  addition to any other remedies that the
Company and Parent may have under this Agreement, the Company and Parent will be
entitled  to  apply to any court of competent jurisdiction for equitable relief,
including  specific  performance  and  injunctions  restraining the Advisor from
committing  or  continuing  any  such  violation  of  this  Agreement.

(b)     The  Advisor  further  agrees  that  no  bond  or other security will be
required  in  obtaining  equitable relief and the Advisor hereby consents to the
issuance  of  an  injunction  and  to  the  ordering  of  specific  performance.

(c)     The  Advisor  further  agrees  that  he  will  be  required  to  sign an
INFORMATION  EVALUATION  AND  NON-DISCLOSURE  AGREEMENT  in  order to accept the
position  on  the  SCTI  Medical  and  Scientific  Advisory  Board.

9.     INDEMNITY

     The  Advisor shall and does hereby agree to defend, indemnify, release, and
save  harmless  the  Company,  or  companies  agents, representatives, servants,
employees,  attorneys,  and assigns from and against any and all suits, actions,
judgments,  damages,  costs, expenses, and attorneys fees incurred in defense of
any  action  or  proceeding  arising  out  of  the performance of this agreement

 10.     NOTICES.

     Any notice, request, demand or other communication required or permitted to
be  given under this Agreement will be sufficient if in writing and if delivered
personally, or sent by certified or registered mail as follows (or to such other
addressee or address as will be set forth in a notice given in the same manner):

IF  TO  THE  ADVISOR:

Dr.  Nikita  Tregubov,  MD.

IF  TO  THE  COMPANY:

Calvin  C.  Cao
CEO/Chairman
Stem  Cell  Therapy  International  Inc.
2203  North  Lois  Avenue,  9th  Floor,  Suite  #901
Tampa,  FL  33607

     Any  such notice will be deemed to be given on the date delivered or mailed
in  the  manner  provided  above.

 11.     WAIVER  OF  BREACH.

     The waiver by the Company or by the Advisor of a breach of any provision of
this Agreement by the other party will not operate, or be construed, as a waiver
of  any  other  breach  of  such  other  party.

12.     ASSIGNMENT.

     This  Agreement  will  inure  to  the  benefit of, and be binding upon, the
Company,  its  successors  and  assigns.  This  Agreement will be binding on the
Advisor,  the  Advisor's  heirs,  executors  or  administrators,  and  legal
representatives.  However,  this Agreement will not be assignable by the Advisor
nor  may  the  obligations  of the Advisor be delegated, without express written
consent  of  the  Company.

 13.     ENTIRE  AGREEMENT.

     This  Agreement  represents  the  entire  understanding  of the parties and
supersedes all previous agreements, oral or written, between the parties and any
modification  of  the  agreement must be in writing and executed by the parties.
This  is  a personal services contract and the Advisor may not assign any rights
or  delegate  any  duties  of  the  Advisor  under  this  agreement.

 14.     APPLICABLE  LAW.

     The  parties  agree  that  this  Agreement  will  be construed and enforced
pursuant  to  the  laws  of  the  Commonwealth  of  Pennsylvania.

     IN WITNESS WHEREOF, the parties have set their hands as of the day and year
first  above  written.

STEM CELL THERAPY INTERNATIONAL, INC.          SCTI MEDICAL AND SCIENTIFIC BOARD
ADVISOR

By:                              BY:  ____________________________
Calvin  C.  Cao,  CEO/Chairman               Dr.  Nikita  Tregubov,  MD.STEM CELL THERAPY INTERNATIONAL, INC.

                      SCTI BUSINESS ADVISORY BOARD AGREEMENT

     THIS  AGREEMENT is made this 5TH day of December, 2005, by and between STEM
CELL THERAPY INTERNATIONAL, INC.; a corporation duly incorporated under the laws
of Nevada, with its principal office located at 2203 North Lois Ave., 9th Floor,
Tampa,  Florida  33594 ("the Company''), and FRED J. VILLELLA as a member of the
SCTI  Business  and  Governmental  Affairs Business Advisory Board, herein ("the
Business  Advisor").

     In  consideration  of the mutual agreements contained in this document, the
parties,  intending  to  be  legally  bound,  agree  as  follows:

 1.     INDEPENDENT  CONTRACTOR.

     The  Business Advisor will be an independent contractor and not an Employee
of  the  Company.

     The  Business  Advisor  will  not  be entitled to receive any compensation,
commissions  or  benefits other than those expressly provided in this Agreement.

2.     SCOPE  OF  DUTIES.

WHEREAS,  The  Business  Advisor  certifies  that  there  are  no  outstanding
agreements  or  obligations  that  conflict  with  any of the provisions of this
Agreement,  or that would preclude or in any way compromise the Business Advisor
in  compliance  with  the  provisions  hereof.

WHEREAS,  The  Company  has  engaged  the  Business Advisor to act as a business
consultant  and  advisor  in  connection  with  the  Company's business matters;

WHEREAS,  The  Business  Advisor has experience in providing business consulting
and  advisory  services to corporations, governmental agencies, partnerships and
other  business  organizations;

NOW  THEREFORE,  in  consideration of, and for the mutual promises and covenants
contained  herein, and for other good and valuable consideration, the receipt of
which  is  hereby  acknowledged,  the  parties  agree  as  follows:

         (1)  PURPOSE.  The  company  hereby  engages  the Business Advisor on a
non-exclusive  basis for the term specified in this Agreement to render business
consulting and advisory services upon the terms and conditions set forth herein.

         (2)  REPRESENTATIONS  OF  THE  BUSINESS  ADVISOR  AND  THE COMPANY. The
Business Advisor represents and warrants to the Company that it is free to enter
into  this  Agreement  and  the  business  consulting and advisory service to be
provided  pursuant  to  this  Agreement  are  not  in  conflict  with  any other
contractual  or  other  obligation  to  which the Business Advisor is bound. The
Company  acknowledges  that the Business Advisor is in the business of providing
business  consulting  and  advisory  services  to others and that nothing herein
contained  shall  be  construed  to  limit  or  restrict the Business Advisor in
conducting  such  business with respect to others, or rendering such services to
others.

         (3)  DUTIES OF THE BUSINESS ADVISOR. During the term of this Agreement,
the  Business  Advisor  will  provide  the  Company with business consulting and
advisory  services as specified below at the request of the Company from time to
time,  provided  that  the  Business  Advisor shall not be required to undertake
duties  not  reasonably  within  the scope of the services in which the Business
Advisor  is  engaged  generally.  In  performance  of these duties, the Business
Advisor  shall  provide  the  Company with the benefits of its best judgment and
efforts.  It  is  understood  and acknowledged by the parties that the amount of
time  spent  rendering  such  business consulting and advisory services shall be
determined  according  to  the  Business  Advisor's  and  the Company's mutually
convenient  schedule.

The  Business  Advisor's business consulting and advisory services shall include
but  are  not  limited  to:

              a)   Corporate  structuring;  set up and administer the California
Office  for  SCTI.

  b)   Interface  with Federal and State governmental agencies to provide access
to,  and help produce to documentation to obtain research grants, secure funding
sources,  participate  in patent filings, obtain special permits and address any
licensing  issues.

   c)  Provide business liaison with Burnham Institute and affiliated clinic and
Physicians  in  the  US  and  Mexico;  and

d)   Provide  general  business  planning, security, development and operations;
and

e)       Assist  with mergers and acquisitions, and other business combinations;
and

     f)   The  Business Advisor will be responsible to do the following as well:

(4)     The  Business  Advisor  agrees  to  participate  in conference calls and
meetings  with  the SCTI Corporate Officers and members of the Company's Medical
and  Scientific Business Advisory Board when his/her schedule allows, to discuss
the  latest technology in stem cell treatments and shall contribute with his/her
recommendations  on  future  progress  and  corporate  operations and direction.

(5)     The  Business  Advisor  will  be required to interact with SCTI treating
Physicians,  Medical and Scientific Advisory Board Members, Corporate Offers and
to  develop  strategic alliances with other corporations, governmental agencies,
research  organizations, universities and individuals outside of the Company for
the advancement of our knowledge and expertise in the treatment of patients with
our  various  stem  cell  Products.

(6)     The  Business  Advisor's roll will be to make sure that the Company will
maintain  its  competitive  edge  both  globally and in the United States in the
field  of stem cell treatments, research and the development of new technologies
and  vertical  markets.
(7)     The Business Advisor will assist in the Development of policies and
Chair the SCTI Bio-Ethics Committee.

3.     COMPENSATION.

     The  Company  shall  issue  ten thousand (10,000) shares of Rule 144 common
stock of the Company to the Business Advisor as compensation for the initial one
year  term  of  this  agreement,  as  follows:

     (a)     Thirty  days  after  the  execution  of this agreement, the Company
shall  issue  five  thousand  (5,000) shares of common stock under rule 144, and

     (b)     Six months after the execution of this agreement, the Company shall
issue  the  remaining  five thousand (5,000) shares common stock under rule 144.

     (c)     Compensation  for  successive renewal years under the terms of this
Agreement  shall  be  issued  at thirty days and six months after renewal in two
increments  of  five  thousand  shares  of  rule  144  common  stock.

4.     TERM.

This  Agreement will become effective on the date of execution and will continue
in  full  force  and  effect for a minimum period of one (1) year and thereafter
from year to year unless and until terminated by a party in accordance with this
Agreement.

5.     TERMINATION.

During  the  minimum  period  of  one  (1)  year,  either  party may immediately
terminate  this  Agreement  for  cause,  upon  written  notice for any breach of
contract,  if  the other party does not cure a material breach of this Agreement
within  thirty  (30)  days  of  receipt of written notice detailing such breach.
After  the  expiration  of  one  (1)  year  from  the  date of execution of this
agreement,  either  party  may  terminate  this  Agreement without cause and for
convenience with fourteen (14) days prior written notice to the other party.  At
any time, the parties may mutually agree in writing to terminate this Agreement.

6.     CONFIDENTIALITY.

          The  Business  Advisor  shall not use or divulge or communicate to any
person  (other  than those whose province it is to know the same or as permitted
or  contemplated  by  this  Agreement  or with the written approval of the other
party  or  as  may  be  required  by  law):
(i)                 any  Confidential  Company  Information;  or
(ii)                any  of  the  terms  of  this  Agreement

     The  Business  Advisor  shall  prevent  the  unauthorized  publication  or
disclosure  of  any such information, materials or documents and ensure that any
person  to  whom  the information, materials or documents are disclosed is aware
that  the  same  is  confidential  and  is covered by a similar duty to maintain
confidentiality.
     The  Business  Advisor shall ensure that any employees, consultants, agents
or  Business  Advisors  are  aware  of  and  comply with the confidentiality and
non-disclosure  provisions  contained  in  this  Section and shall indemnify the
Company  against  any loss or damage which the Company may sustain or incur as a
result  of  any  breach  of  the  terms  hereof  by the Business Advisor, or any
employees,  consultants,  agents  or  Business  Advisors.
     CONFIDENTIAL  INFORMATION.

     The Business Advisor shall not directly or indirectly, communicate,
disclose or divulge to any person or entity, or use for their own benefit or the
benefit of any person or entity, any knowledge or information which the Business
Advisor may have acquired, no matter from whom or on what matter such knowledge
or information may have been acquired from the Company.
<PAGE>
These  provisions shall survive the expiration or termination of this Agreement.

7.     COVENANT  NOT  TO  COMPETE.

     The  Business Advisor, during the Term hereof, and for an additional period
of  two  years  thereafter  (the  ``Non-competition  Term''),  may  not:

(a)     Engage  or  participate  in  or  become  employed by, or render Business
Advisory  or  other  services  to,  any  business  entity that competes with the
Company  in  the  Ukraine  or  the  Dominican  Republic.

     If  the  foregoing  provision  is determined to be invalid by reason of the
length  of  any  period  or the size of the area set forth, such period of time,
such  area  or both will be considered to be reduced to a period of time or area
that  will  cure  such  invalidity.

(b)     Directly  or  indirectly  solicit  or induce any person, corporation, or
other  entity  that is a customer of the Company at the time of the execution of
this  agreement  or  that  was a customer at any time within the one-year period
immediately preceding such termination to become a customer of any other person,
corporation,  or  other  entity  competing  with  the Company or its Parent. The
Business  Advisor  further  agrees  that  he  or  she will not approach any such
person,  corporation,  or  other  entity  for  such  purposes.

(c)     Directly  or  indirectly solicit or induce any person who is an Employee
of  the  Company  or  its  Parent  to  become  employed  by  any person, firm or
corporation  competing  with the Company or its Parent, or approach any Employee
for  such  purpose.

(d)     Disclose  any  proprietary or confidential information of the Company or
its Parent relating to (i) the customers, clients, employees and accounts of the
Company  or  its  Parent,  including  but  not  limited  to  the identity of the
Company's  or  its  Parent's  customers  if  such  identity  is  proprietary  or
confidential;  (ii)  the  Company's  or  its Parent's business methods, systems,
plans,  policies,  and personnel; or (iii) the technical data, trade secrets, or
know-how  of the Company or its Parent, including, but not limited to, research,
product  plans, products, services, markets, software, developments, inventions,
processes,  formulas,  technology,  designs,  drawings,  engineering,  hardware,
configuration  information,  marketing,  finances  or other business information
disclosed  by  the Company or its Parent, either directly or indirectly, whether
in  writing,  orally  or  by  drawings  or  inspection  of  parts  or equipment.

8.     ARBITRATION  OF  DISPUTES.

(a)     The  Company  and  the  Business  Advisor  agree  that  any  dispute  or
controversy  arising  out  of  or  relating to any interpretation, construction,
performance  or  breach  of this Agreement, will be settled by arbitration to be
held  in Philadelphia County, Pennsylvania, in accordance with the rules then in
effect  of  the  American  Arbitration  Association.  The  arbitrator  may grant
injunctions  or  other  relief  in  the  dispute  or  controversy.

(b)     The  decision of the arbitrator will be final, conclusive and binding on
the  parties  to  the  arbitration.  Judgment may be entered on the arbitrator's
decision  in  any  court of competent jurisdiction. The Company and The Business
Advisor  will  each pay one-half of the cost and expenses of the arbitration and
each  will  separately  pay  its  respective  counsel  fees  and  expenses.

     The  Business  Advisor acknowledges that the services to be rendered by the
Business  Advisor  are  of a special, unique and extraordinary character, and in
connection  with  such  services,  the  Business  Advisor  will  have  access to
confidential  information  vital  to the Company's and its Parent's business. By
reason  of  this,  the  Business  Advisor  agrees  that  if the Business Advisor
violates  any  of  the  provisions  of  this  Agreement  with  respect  to
non-competition,  diversion  of  the  Company's  and  its  Parent's  clients  or
employees,  or  confidentiality,  the  Company  and  the  Parent  would  sustain
irreparable  harm,  and  therefore,  in  addition to any other remedies that the
Company and Parent may have under this Agreement, the Company and Parent will be
entitled  to  apply to any court of competent jurisdiction for equitable relief,
including  specific performance and injunctions restraining the Business Advisor
from  committing  or  continuing  any  such  violation  of  this  Agreement.

(b)     The  Business Advisor further agrees that no bond or other security will
be  required  in  obtaining  equitable  relief  and  the Business Advisor hereby
consents  to  the  issuance  of  an  injunction  and to the ordering of specific
performance.

(c)     The  Business Advisor further agrees that he will be required to sign an
INFORMATION & PRODUCT EVALUATION AND NON-DISCLOSURE AGREEMENT in order to accept
the  position  on  the  SCTI  Business  Advisory  Board.

9.     INDEMNITY

     The  Business  Advisor  shall  and  does hereby agree to defend, indemnify,
release,  and  save  harmless the Company, or companies agents, representatives,
servants,  employees, attorneys, and assigns from and against any and all suits,
actions,  judgments,  damages,  costs,  expenses, and attorneys fees incurred in
defense  of  any  action  or  proceeding  arising out of the performance of this
agreement

 10.     NOTICES.

     Any notice, request, demand or other communication required or permitted to
be  given under this Agreement will be sufficient if in writing and if delivered
personally, or sent by certified or registered mail as follows (or to such other
addressee or address as will be set forth in a notice given in the same manner):

If  to  the  Business  Advisor:

Fred  J.  Villella

____________________________________

and
____________________________________

If  to  the  Company:

Calvin  C.  Cao
CEO/Chairman
Stem  Cell  Therapy  International  Inc.
2203  North  Lois  Avenue,  9th  Floor,  Suite  #901
Tampa,  FL  33607

     Any  such notice will be deemed to be given on the date delivered or mailed
in  the  manner  provided  above.

 11.     WAIVER  OF  BREACH.

     The  waiver  by  the  Company or by the Business Advisor of a breach of any
provision  of  this  Agreement  by  the  other  party  will  not  operate, or be
construed,  as  a  waiver  of  any  other  breach  of  such  other  party.

12.     ASSIGNMENT.

     This  Agreement  will  inure  to  the  benefit of, and be binding upon, the
Company,  its  successors  and  assigns.  This  Agreement will be binding on the
Business Advisor, the Business Advisor's heirs, executors or administrators, and
legal  representatives.  However,  this  Agreement will not be assignable by the
Business  Advisor  nor may the obligations of the Business Advisor be delegated,
without  express  written  consent  of  the  Company.

 13.     ENTIRE  AGREEMENT.

     This  Agreement  represents  the  entire  understanding  of the parties and
supersedes all previous agreements, oral or written, between the parties and any
modification  of  the  agreement must be in writing and executed by the parties.
This is a personal services contract and the Business Advisor may not assign any
rights  or  delegate  any  duties  of the Business Advisor under this agreement.

 14.     APPLICABLE  LAW.

     The  parties  agree  that  this  Agreement  will  be construed and enforced
pursuant  to  the  laws  of  the  Commonwealth  of  Pennsylvania.

     IN WITNESS WHEREOF, the parties have set their hands as of the day and year
first  above  written.

Stem Cell Therapy International, Inc.                          SCTI Business and
Governmental Affairs Business Advisor

By:                              BY:  ____________________________
Calvin  C.  Cao,  CEO/Chairman               Fred  J,  Villella

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]